AMLX Q3 2024 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMLXAmylyx Pharmaceuticals, Inc.

$1B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$416,000-99.6% YoY

Gross Profit

-$393,000-94.5% margin

Operating Income

-$76M-18187.7% margin

Net Income

-$73M-17476.9% margin

EPS (Diluted)

$-1.07

QoQ Revenue Growth

+140.7%

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$42M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$251M

Total Liabilities

$55M

Stockholders' Equity

$196M

Cash & Equivalents

$72M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$416,000	$103M	-99.6%
Gross Profit	-$393,000	$97M	-100.4%
Operating Income	-$76M	$19M	-504.2%
Net Income	-$73M	$21M	-448.0%